JP2010120974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010120974A5 JP2010120974A5 JP2010040362A JP2010040362A JP2010120974A5 JP 2010120974 A5 JP2010120974 A5 JP 2010120974A5 JP 2010040362 A JP2010040362 A JP 2010040362A JP 2010040362 A JP2010040362 A JP 2010040362A JP 2010120974 A5 JP2010120974 A5 JP 2010120974A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- isoxazole
- pyrimidinyl
- acetylamino
- methylphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000725 suspension Substances 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000002199 base oil Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- MZIXITYNBSSIAX-UHFFFAOYSA-N 2-(2-bromophenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)Br)ON=2)C=2N=CN=CC=2)=C1 MZIXITYNBSSIAX-UHFFFAOYSA-N 0.000 claims 1
- OHMPXDCOVKOOAN-UHFFFAOYSA-N 2-(2-chloro-6-fluorophenyl)-n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2F)Cl)=C1C1=CC=NC=N1 OHMPXDCOVKOOAN-UHFFFAOYSA-N 0.000 claims 1
- QOGGUCJFELPAEY-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(2,4-difluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound FC1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 QOGGUCJFELPAEY-UHFFFAOYSA-N 0.000 claims 1
- PMRBBABDBAMJIN-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(2-fluoro-4-methoxyphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound FC1=CC(OC)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 PMRBBABDBAMJIN-UHFFFAOYSA-N 0.000 claims 1
- BWJBUFSDWGGBFI-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)Cl)ON=2)C=2N=CN=CC=2)=C1 BWJBUFSDWGGBFI-UHFFFAOYSA-N 0.000 claims 1
- AQMVNECEJJQRQJ-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(4-chlorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(Cl)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 AQMVNECEJJQRQJ-UHFFFAOYSA-N 0.000 claims 1
- JZLOFCLTDFXBCB-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-[3-(4-fluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1C1=NOC(NC(=O)CC=2C(=CC=CC=2)Cl)=C1C1=CC=NC=N1 JZLOFCLTDFXBCB-UHFFFAOYSA-N 0.000 claims 1
- AELDWGOWMGTPJH-UHFFFAOYSA-N 2-(2-methylphenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(NC(=O)CC=3C(=CC=CC=3)C)ON=2)C=2N=CN=CC=2)=C1 AELDWGOWMGTPJH-UHFFFAOYSA-N 0.000 claims 1
- HZMVXCOGADXULI-UHFFFAOYSA-N 2-(3-methylphenyl)-n-[3-(3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]acetamide Chemical compound CC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C=C(C)C=CC=2)C=2N=CN=CC=2)=C1 HZMVXCOGADXULI-UHFFFAOYSA-N 0.000 claims 1
- PJFIMAKNTIRBJV-UHFFFAOYSA-N CC1=CC=CC=C1CC(=O)NC2=C(C=NO2)C3=NC=NC=C3 Chemical compound CC1=CC=CC=C1CC(=O)NC2=C(C=NO2)C3=NC=NC=C3 PJFIMAKNTIRBJV-UHFFFAOYSA-N 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002270 dispersing agent Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- XKEMXPHDWNBNDO-UHFFFAOYSA-N n-[3-(1,3-benzodioxol-4-yl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(2-chlorophenyl)acetamide Chemical compound ClC1=CC=CC=C1CC(=O)NC1=C(C=2N=CN=CC=2)C(C=2C=3OCOC=3C=CC=2)=NO1 XKEMXPHDWNBNDO-UHFFFAOYSA-N 0.000 claims 1
- UZDRQZQLGAILEW-UHFFFAOYSA-N n-[3-(2,4-difluorophenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C(=CC(F)=CC=2)F)C=2N=CN=CC=2)=C1 UZDRQZQLGAILEW-UHFFFAOYSA-N 0.000 claims 1
- JZFXMSKMTAEMOB-UHFFFAOYSA-N n-[3-(2-fluoro-5-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-phenylacetamide Chemical compound CC1=CC=C(F)C(C=2C(=C(NC(=O)CC=3C=CC=CC=3)ON=2)C=2N=CN=CC=2)=C1 JZFXMSKMTAEMOB-UHFFFAOYSA-N 0.000 claims 1
- YCKFJJBQSKBYBQ-UHFFFAOYSA-N n-[3-(4-fluoro-3-methylphenyl)-4-pyrimidin-4-yl-1,2-oxazol-5-yl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC2=C(C(=NO2)C=2C=C(C)C(F)=CC=2)C=2N=CN=CC=2)=C1 YCKFJJBQSKBYBQ-UHFFFAOYSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 239000001993 wax Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010040362A JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007035916 | 2007-02-16 | ||
| JP2010040362A JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558013A Division JP4588791B2 (ja) | 2007-02-16 | 2008-02-15 | 微粒子油性懸濁液を含む医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010120974A JP2010120974A (ja) | 2010-06-03 |
| JP2010120974A5 true JP2010120974A5 (cg-RX-API-DMAC7.html) | 2011-02-03 |
Family
ID=39689861
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558013A Expired - Fee Related JP4588791B2 (ja) | 2007-02-16 | 2008-02-15 | 微粒子油性懸濁液を含む医薬組成物 |
| JP2010040362A Pending JP2010120974A (ja) | 2007-02-16 | 2010-02-25 | 微粒子油性懸濁液を含む医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008558013A Expired - Fee Related JP4588791B2 (ja) | 2007-02-16 | 2008-02-15 | 微粒子油性懸濁液を含む医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8309138B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2123255B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP4588791B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101434706B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101610754A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008215659B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2677842C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2423929T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008099615A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ591810A (en) | 2008-09-17 | 2012-12-21 | Chiasma Inc | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid |
| CN103655512B (zh) * | 2013-12-12 | 2015-05-20 | 海南海力制药有限公司 | 一种硝酸芬替康唑阴道软胶囊及其制备方法 |
| EP4527456A3 (en) | 2015-02-03 | 2025-05-21 | Amryt Endo, Inc. | Treating acromegaly with oral octreotide |
| US11576914B2 (en) | 2017-07-26 | 2023-02-14 | The Doshisha | Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof |
| EP3668957A4 (en) * | 2017-08-17 | 2021-06-02 | University of Delaware | Furan based compositions and methods of making thereof |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8546591A (en) | 1990-09-13 | 1992-04-15 | Smithkline Beecham Corporation | Non-aqueous liquid oral suspensions |
| MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| JPH0616556A (ja) | 1992-07-02 | 1994-01-25 | Yoshitomi Pharmaceut Ind Ltd | 難溶性薬物含有製剤 |
| US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| US5651983A (en) | 1993-02-26 | 1997-07-29 | The Procter & Gamble Company | Bisacodyl dosage form for colonic delivery |
| JPH07138151A (ja) | 1993-11-15 | 1995-05-30 | Kanebo Ltd | ソフトカプセル剤及びその製造方法 |
| DE10399017I1 (de) | 1995-02-13 | 2012-05-16 | Searle & Co | Substituierte isoxazole zur Behandlung von entzuendung |
| JPH1081621A (ja) | 1996-04-01 | 1998-03-31 | Takeda Chem Ind Ltd | 経口投与用医薬組成物 |
| JP2000516244A (ja) | 1996-08-22 | 2000-12-05 | リサーチ・トライアングル・ファーマシューティカルズ | 水不溶性物質の微粒子を含む組成物およびその製造方法 |
| US5736151A (en) * | 1996-12-09 | 1998-04-07 | Pharmacia & Upjohn Company | Antibiotic oil suspensions |
| TR200000235T2 (tr) | 1997-05-22 | 2000-05-22 | G.D. Searle &Co. | p38 kinaz inhibitörleri olarak ikame edilmiş pirazoller. |
| CA2320087C (en) | 1998-02-09 | 2006-12-19 | Joel Bolonick | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| JPH11302156A (ja) | 1998-04-16 | 1999-11-02 | Tanabe Seiyaku Co Ltd | ポリペプチドの微粒子化方法 |
| JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | ５−アミノイソキサゾール誘導体 |
| PE20001227A1 (es) * | 1998-10-30 | 2000-11-06 | Hoffmann La Roche | Procesos para producir una composicion de isotretinoina |
| AU769610B2 (en) * | 1998-12-23 | 2004-01-29 | Amgen, Inc. | Polyol/oil suspensions for the sustained release of proteins |
| WO2000039116A1 (en) | 1998-12-25 | 2000-07-06 | Teikoku Hormone Mfg. Co., Ltd. | Aminopyrazole derivatives |
| WO2000040220A1 (en) | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| SK286371B6 (sk) * | 1999-02-23 | 2008-08-05 | Merck & Co., Inc. | Farmaceutický prostriedok |
| KR100449215B1 (ko) | 1999-04-23 | 2004-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 5-피리딜-1,3-아졸 화합물, 이의 제조 방법 및 이의 용도 |
| DE60016617T2 (de) * | 1999-10-01 | 2005-04-28 | Natco Pharma Ltd., Banjara Hills | Magensaftresistente gelartige weichkapsel |
| IN192188B (cg-RX-API-DMAC7.html) * | 2000-06-16 | 2004-03-13 | Ranbaxy Lab Ltd | |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE60104206T2 (de) | 2000-09-22 | 2005-09-22 | Galephar M/F | Halbfeste arzneizubereitung enthaltend isotretinoin |
| KR20040073493A (ko) | 2001-12-20 | 2004-08-19 | 파마시아 코포레이션 | 경구 투여용 제약 현탁액 |
| JP4611641B2 (ja) | 2002-03-20 | 2011-01-12 | エラン ファーマ インターナショナル，リミティド | Ｍａｐキナーゼ阻害剤のナノ粒子組成物 |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| ATE374201T1 (de) | 2002-08-06 | 2007-10-15 | Hoffmann La Roche | 6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase |
| DE10237883A1 (de) | 2002-08-19 | 2004-03-04 | Merckle Gmbh Chem.-Pharm. Fabrik | Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie |
| AU2003255843A1 (en) | 2002-08-23 | 2004-03-11 | Ionix Pharmaceuticals Limited | 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain |
| JP2004099442A (ja) | 2002-09-04 | 2004-04-02 | Nisshin Pharma Inc | 難溶性薬物含有製剤およびその製造方法 |
| WO2004022555A1 (en) | 2002-09-06 | 2004-03-18 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use in the treatment of ischemic diseases |
| EA011708B1 (ru) | 2002-12-18 | 2009-04-28 | Алгоркс Фармасьютикалз, Инк. | Применение транс- капсаицина |
| ES2264795T3 (es) | 2003-02-14 | 2007-01-16 | Pfizer Products Inc. | Triazolo-piridinas como compuestos antiinflamatorios. |
| CA2515939A1 (en) | 2003-02-14 | 2004-09-02 | Smithkline Beecham Corporation | Novel compounds |
| WO2004073692A1 (ja) | 2003-02-18 | 2004-09-02 | Yamashita, Shinji | 難水溶性薬物のハードカプセル剤 |
| JP2005013938A (ja) | 2003-06-27 | 2005-01-20 | Canon Inc | 脱色装置及び方法 |
| US20060151899A1 (en) | 2003-08-06 | 2006-07-13 | Akira Kato | Process for producing drug ultramicroparticle and apparatus therefor |
| JP5096658B2 (ja) | 2003-10-06 | 2012-12-12 | 株式会社三協 | 生物学的利用能を向上させたソフトカプセル |
| GB0402143D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
| AU2005219525B2 (en) | 2004-02-27 | 2011-08-18 | F. Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
| SI2275098T1 (sl) * | 2004-05-04 | 2012-12-31 | Hormos Medical Ltd. | Nove oralne formulacije ospemifena |
| US8758821B2 (en) | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
| CN101080404B (zh) * | 2004-12-28 | 2011-06-08 | Aska制药株式会社 | 嘧啶基异噁唑衍生物 |
| JP2007039408A (ja) | 2005-08-05 | 2007-02-15 | Unitec Foods Co Ltd | 微粉化クレアチンとその製造方法 |
-
2008
- 2008-02-15 KR KR1020097019114A patent/KR101434706B1/ko active Active
- 2008-02-15 US US12/526,825 patent/US8309138B2/en active Active
- 2008-02-15 WO PCT/JP2008/000230 patent/WO2008099615A1/ja not_active Ceased
- 2008-02-15 JP JP2008558013A patent/JP4588791B2/ja not_active Expired - Fee Related
- 2008-02-15 EP EP08710384.2A patent/EP2123255B1/en active Active
- 2008-02-15 ES ES08710384T patent/ES2423929T3/es active Active
- 2008-02-15 AU AU2008215659A patent/AU2008215659B2/en active Active
- 2008-02-15 CN CNA2008800051218A patent/CN101610754A/zh active Pending
- 2008-02-15 CA CA2677842A patent/CA2677842C/en active Active
-
2010
- 2010-02-25 JP JP2010040362A patent/JP2010120974A/ja active Pending